Non-small cell lung cancer (NSCLC) with a specific mutation in the KRAS gene that has metastasized to the central nervous system has been difficult to treat. Joshua K. Sabari, MD, assistant professor in the Department of Medicine at NYU Grossman School of Medicine and a member of NYU Langone Health’s Perlmutter Cancer Center, presented promising results for people with NSCLC from the phase 1b KRYSTAL-1 clinical trial of the cancer drug adagrasib at the 2022 annual conference of the American Society of Clinical Oncology.
“Central nervous system metastases occur in 27 percent to 42 percent of patients with KRAS G12C-mutation NSCLC at diagnosis,” Dr. Sabari says. “These patients have a median overall survival of approximately five months, posing a serious clinical challenge.”
Read more from Forbes.